BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 9, 2009
View Archived Issues
Idenix, GSK Team Up in $450M HIV Deal
Idenix Pharmaceuticals Inc. has granted London-based GlaxoSmithKline plc worldwide rights to IDX899, a potential treatment for HIV/AIDS, in a deal that could bring in a potential $450 million for the U.S-based biotech. (BioWorld Today)
Read More
Biogen Hits Earnings Estimates, Though Tysabri Sales Fall Short
Read More
FDA Accepts Roxro's NDA for Intranasal Non-Narcotic Painkiller
Read More
Dems Pledge Health Reform Despite Loss of Daschle
Read More
Avigen's Board Rejects BVF Bid; Urges Shareholders to Pass
Read More
GTC's ATryn Wins One OK, Loses on Broader Indication
Read More
Other News To Note
Read More
Financings Roundup
Read More